Keywords: Generex Biotech, Antigen Express, Spin-out, Vaccine technology, Buccal drug delivery, Appointments
Generex unveils strategic development plan, including Antigen Express spin-out
Article | 01 April 2011
USA-based Generex Biotechnology (OTC Bulletin Board: GNBT) unveiled management's strategic development plan for the company's future growth at a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
